- Friday, May 5, 2023
9:00 AM – 9:15 AM ET
Welcome and Introduction
9:00 AM – 9:15 AM ET
Welcome and Introduction
Time Zone: ET
9:15 AM – 9:50 AM ET
Session 16: HER2-Positive Metastatic Breast Cancer: Where Are We Headed?
9:15 AM – 9:50 AM ET
Session 16: HER2-Positive Metastatic Breast Cancer: Where Are We Headed?Time Zone: ETPresenter: – University of California, Los Angeles
Sara Hurvitz, MD – University of California, Los Angeles ### 1186881###Presenter###Professor of Medicine###University of California, Los Angeles###Presenter: – University of California, Los Angeles
### 9:50 AM – 10:00 AM ET
Live Q&A
9:50 AM – 10:00 AM ET
Live Q&ATime Zone: ETModerator: – Sarah Cannon Research Institute (SCRI)
Speaker: – University of California, Los Angeles
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Sara Hurvitz, MD – University of California, Los Angeles ### 1186881###Speaker###Professor of Medicine###University of California, Los Angeles###Speaker: – University of California, Los Angeles
### 10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
Time Zone: ET
10:15 AM – 11:15 AM ET
Case-Based Discussion on Management of Select Adverse Events
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
Time Zone: ET
11:15 AM – 11:30 AM ET
Break
11:15 AM – 11:30 AM ET
Break
Time Zone: ET
11:30 AM – 12:05 PM ET
Session 17: Immunotherapy for Breast Cancer
11:30 AM – 12:05 PM ET
Session 17: Immunotherapy for Breast CancerTime Zone: ETPresenter: – International Breast Cancer Center , IBCC
Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC ### 1186877###Presenter###Head###International Breast Cancer Center , IBCC###Presenter: – International Breast Cancer Center , IBCC
### 12:05 PM – 12:15 PM ET
Live Q&A
12:05 PM – 12:15 PM ET
Live Q&ATime Zone: ETModerator: – Sarah Cannon Research Institute (SCRI)
Speaker: – International Breast Cancer Center , IBCC
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC ### 1186877###Speaker###Head###International Breast Cancer Center , IBCC###Speaker: – International Breast Cancer Center , IBCC
### 12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
Time Zone: ET
12:30 PM – 1:15 PM ET
Session 18: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etc
12:30 PM – 1:15 PM ET
Session 18: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etcPresenter: – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology ### 1879169###Presenter###Medical Oncologist###Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology###Presenter: – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
### 1:15 PM – 1:35 PM ET
Break
1:15 PM – 1:35 PM ET
Break
Time Zone: ET
1:35 PM – 1:50 PM ET
Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - YES
1:35 PM – 1:50 PM ET
Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - YESTime Zone: ETPresenter: – Princess Margaret Cancer Centre
David Cescon, MD, PhD – Princess Margaret Cancer Centre ### 1765982###Presenter###Medical Oncologist and Clinician Scientist###Princess Margaret Cancer Centre###Presenter: – Princess Margaret Cancer Centre
### 1:50 PM – 2:05 PM ET
Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - NO
1:50 PM – 2:05 PM ET
Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - NOTime Zone: ETPresenter: – Mass General Cancer Center, Harvard Medical School
Dejan Juric, MD – Mass General Cancer Center, Harvard Medical School ### 1744695###Presenter###Director, Termeer Center for Targeted Therapies###Mass General Cancer Center, Harvard Medical School###Presenter: – Mass General Cancer Center, Harvard Medical School
### 2:05 PM – 2:25 PM ET
Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - DISCUSSION
2:05 PM – 2:25 PM ET
Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - DISCUSSIONTime Zone: ETModerator: – Sarah Cannon Research Institute (SCRI)
Panelist: – Princess Margaret Cancer Centre
Panelist: – Mass General Cancer Center, Harvard Medical School
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ David Cescon, MD, PhD – Princess Margaret Cancer Centre ### 1765982###Panelist###Medical Oncologist and Clinician Scientist###Princess Margaret Cancer Centre###Panelist: – Princess Margaret Cancer Centre
### @@@ Dejan Juric, MD – Mass General Cancer Center, Harvard Medical School ### 1744695###Panelist###Director, Termeer Center for Targeted Therapies###Mass General Cancer Center, Harvard Medical School###Panelist: – Mass General Cancer Center, Harvard Medical School
### 2:20 PM – 2:45 PM ET
Break
2:25 PM – 2:45 PM ET
Break
Time Zone: ET
2:45 PM – 3:20 PM ET
Session 20: Beyond Immunotherapy: Novel Agents in TNBC
2:45 PM – 3:20 PM ET
Session 20: Beyond Immunotherapy: Novel Agents in TNBCTime Zone: ETPresenter: – The University of Chicago
Rita Nanda, MD (she/her/hers) – The University of Chicago ### 1949812###Presenter###Director of Breast Oncology, Associate Professor of Medicine###The University of Chicago###Presenter: – The University of Chicago
### she/her/hers3:20 PM – 3:30 PM ET
Live Q&A
3:20 PM – 3:30 PM ET
Live Q&ATime Zone: ETModerator: – Sarah Cannon Research Institute (SCRI)
Speaker: – The University of Chicago
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Rita Nanda, MD (she/her/hers) – The University of Chicago ### 1949812###Speaker###Director of Breast Oncology, Associate Professor of Medicine###The University of Chicago###Speaker: – The University of Chicago
### she/her/hers3:30 PM – 3:45 PM ET
Break
3:30 PM – 3:45 PM ET
Break
Time Zone: ET
3:45 PM – 4:20 PM ET
Session 21: Biosimilars in Breast Cancer Therapy
3:45 PM – 4:20 PM ET
Session 21: Biosimilars in Breast Cancer TherapyTime Zone: ET
William Gradishar, MD, FASCO, FACP ### 1929925###Presenter#########Presenter:
### 4:20 PM – 4:30 PM ET
Live Q&A
4:20 PM – 4:30 PM ET
Live Q&ATime Zone: ETModerator: – Sarah Cannon Research Institute (SCRI)
Speaker:
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ William Gradishar, MD, FASCO, FACP ### 1929925###Speaker#########Speaker:
### 4:30 PM – 4:45 PM ET
Break
4:30 PM – 4:45 PM ET
Break
Time Zone: ET
4:45 PM – 5:20 PM ET
Session 22: HER2-Low Breast Cancer: Limits of Testing and Where to Go from Here
4:45 PM – 5:20 PM ET
Session 22: HER2-Low Breast Cancer: Limits of Testing and Where to Go from HereTime Zone: ETPresenter: – Dana-Farber Cancer Institute, Harvard Medical School
Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Presenter###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###Presenter: – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his5:20 PM – 5:30 PM ET
Live Q&A
5:20 PM – 5:30 PM ET
Live Q&ATime Zone: ETModerator: – Sarah Cannon Research Institute (SCRI)
Speaker: – Dana-Farber Cancer Institute, Harvard Medical School
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Speaker###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###Speaker: – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his